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Abstract
Background: Reactions are commonly associated with the chemotherapy of onchocerciasis.
However unmanageable reactions are uncommon when ivermectin (Mectizan®) is used for the
treatment of this infection, and this drug has proved to be a great improvement over previously
used agents. Serious adverse events (SAE) nevertheless have occurred, and there is considerable
concern about the negative effect such events may have on mass drug administration programs.
This paper reviews the basic pathogenic mechanisms that can be involved in the destruction of
microfilaria by chemotherapeutic agents. A central challenge to filarial chemotherapy is the need
to remove parasites from biologically sensitive tissues, a more difficult medical challenge than
eliminating nematodes from the gastrointestinal tract.
Explanations for the etiology of the serious adverse reactions occurring with ivermectin treatment
in specific geographic areas where there is coincident heavy Loa loa infections are hampered by a
lack of specific pathological case material. Ways to investigate these possibilities are reviewed.
Possible pathogenic mechanisms include embolic vascular pathology accompanied by local
inflammation, blood brain barrier mdr1 abnormalities, and genetic predisposition to excessive
inflammatory responses.
Conclusion: It is important to keep ivermectin, and all its associated adverse clinical events, in
perspective with the many other chemotherapeutic agents in general use – many of which produce
serious adverse events even more frequently than does ivermectin. Currently available evidence
indicates that the pathogenesis of the Loa-associated adverse reactions are probably related to
inflammatory responses to microfilariae in specific tissues. However, the possibility of genetic
predispositions to pathology should also be considered.
Background
Ivermectin is an extremely safe drug when used in humans
and other animals for the treatment and control of nema-
tode and ectoparasite infections [1–3]. The destruction of
nematodes in tissues, with a comparatively large mass of
foreign material to remove, is a challenge to the host's
defense systems. One might reasonably expect this proc-
ess to be accompanied by overt clinical reactions. Indeed,
it has been known for decades that anti-filarial chemo-
therapy is associated with excessive and sometimes fatal
host reactions, the severity and clinical consequences of
which depend on the therapeutic agent used [1]. The use
of ivermectin for the treatment and control of Onchocerca
volvulus infections is highly advantageous in this context,
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as this drug produces far fewer serious adverse reactions
than the previous drug of choice, diethylcarbamazine
(DEC) [1,4].
There is a need to better understand the SAEs associated
with anti-filarial chemotherapy, in particular the fatalities
that have occurred in a small number of individuals who
had recently been administered a standard dose of iver-
mectin; these individuals had coincident high loads of cir-
culating Loa loa microfilariae (Mf). These are people, for a
large part, living in a specific region of Cameroon – and
who died after falling into a coma within four days of
treatment [5–7]. This unexpected and unprecedented sit-
uation has rightly caused much concern, both from the
medical aspect and from a programmatic perspective. This
drug has been a key to the success of the major global con-
trol program for onchocerciasis. The program has been in
existence now for over fifteen years, and is now under
threat of interruption in the many endemic areas because
of this unexplained and extremely serious toxicity.
Any discussion of the pathogenesis of these SAEs must be
prefaced by the fact that very little pathological material or
data has been collected on these L. loa-ivermectin patients
to date, and thus such a discussion must be made with a
strong theoretical rather than factual basis. The presence
of high loads of Loa microfilariae strongly suggests that
there is a possibility that the SAEs are associated with the
destruction of these parasites in sensitive tissues such as
the central nervous system (CNS). It is pertinent therefore
to first review what is known about the basic mechanisms
of parasite death and removal of Mf from the human host
by way of introduction to mechanisms that may be
involved in these adverse reactions. It is also important to
compare the clinical events seen in Cameroon with other
medical events and conditions with a similar presentation
or history; this may be the only practical way to develop
plausible theories about the pathogenesis of these specific
adverse reactions.
Pathological events in human onchocerciasis
General Aspects
Filarial parasites are relatively large organisms. It is a
remarkable biological phenomenon that they can reside
in tissues, or circulate in the blood and lymph in large
numbers, whilst only causing minimal clinical response
and little or no apparent pathology. Some filariae, such as
Mansonella perstans, despite their considerable prevalence,
cause no significant pathology in contrast to the filariae
that cause onchocerciasis and lymphatic filariasis; the
pathobiology underlying these differences remains poorly
understood but nevertheless intriguing.
The central pathogenic event in the development of clini-
cal disease in onchocerciasis is thought to be the destruc-
tion of Mf and the associated inflammatory events, such
as local tissue damage and degradation of host structures
(constitutive collagen fibers, pigmentary cells) [8]. The
adult-containing nodules in themselves are usually more
an aesthetic problem and cause no major or systemic clin-
ical effects (although the presence of such large antigenic
entities in the host in all likelihood has effects other than
simply being the source of new Mf). Other phenomena,
such as immune complex pathology, autoimmune disease
and secondary infections, should be considered as possi-
ble factors in this disease complex [8]. For example, there
is a direct correlation between anti-collagen antibody lev-
els and the development of chronic disease, and these lev-
els of antibodies exceed those seen in major autoimmune
diseases such as system lupus erythematosus (Mackenzie,
unpublished observations). The possibility that these
pathogenic mechanisms may be involved cannot be
ignored; obviously, much still remains to be understood.
Onchocerciasis patients are in a delicate immunological
balance with their parasites, and host responses are clearly
integral to the clinical outcome [8,9]. Many onchocercia-
sis patients carry >100 million Mf in the immunologically
sensitive connective tissues of the skin, yet experience
minimal discomfort or severe clinical effects, at least not
in the short term; this same phenomenon apparently exist
with Loa infections This phenomenon of tolerance con-
trasts with the situation occurring in onchocercal patients
with "sowda" (reactive onchodermatitis) who appear to
not be in this quiescent state and suffer tremendously
from constant and extremely disquieting dermal pathol-
ogy; these patients also react severely to treatment with
filariacides [10].
Treatment with filariacides disturbs this balance. Further-
more, immune responses following administration of
these drugs play a key role in parasite clearance (i.e., effi-
cacy). The involvement of the immune system in the anti-
filarial efficacy of ivermectin has been raised repeatedly
[11–13]. This phenomenon occurs with other filarial par-
asites as well, although not always as strikingly as in
onchocerciasis. Differences in the contribution of
immune responses to chemotherapeutic success among
the filariases may reflect the tissue or organs involved in
the parasitism (and the ability of that tissue to handle
dying Mf), or perhaps a more complicated phenomenon
involving the degree of adaptation of the parasite species
to the host. The fundamental phenomenon of a balance
between the host and the parasite maintained by parasite-
derived immunosuppression and other mechanisms is
central to the persistence of these infections in the
untreated state.
Recently, it has also been proposed that endosymbiotic
bacteria (Wolbachia spp.) infecting filariae exacerbate theFilaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S5
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pathology of onchocerciasis [14]. The literature concern-
ing most human filariae, including O. volvulus, is replete
with reports and details of anaphylactoid reactions –
known as Mazzotti reactions (after the Mexican Luis Maz-
zotti, who first described them) – associated with chemo-
therapy. It is now thought possible that these reactions
may be directed, at least in part, to bacterial rather than
nematode antigens.
It must be emphasized that it is the rule rather than the
exception for a treated individual infected with onchocer-
ciasis to experience some form of clinical discomfort or
systemic change after treatment with antifilarial drugs
(Table 1). The frequency and severity of such reactions dif-
fer with the chemotherapeutic agent used, but all cause at
least some undesirable effect. It is the degree of these
effects that are of interest here, with special attention paid
to the severe, sometimes fatal reactions that have occurred
in one L. loa endemic area (Cameroon). A key question is
whether the pathogenesis of the severe cases simply
reflects an unusual enhancement of commonly encoun-
tered processes, or involves new processes that are not
seen in the vast majority of onchocerciasis patients.
Specific events associated with microfilarial destruction
Events surrounding the death and removal of Mf are of
primary importance in any discussion of the pathogenesis
of SAEs encountered during the treatment of filarial infec-
tions. Much of the information to date related to this phe-
nomenon is taken from data collected with the treatment
of O. volvulus and L. loa with older agents such as DEC
[15]. Events associated with Mf destruction are noted in
Table 2. Many of the events following treatment with iver-
mectin are similar to those seen with DEC although to
lesser in intensity and rate.
The body in most cases can, although with some discom-
fort, handle the events related to Mf destruction and
removal, and return to a state of relative normality within
24–48 hr after anti-filarial drug administration. However,
these reactions can exceed the capacity of the individual to
manage them, for example, when topical DEC is used
[15]. This latter treatment can lead to overwhelming local
dermal reactions and associated systemic effects that are
too severe for the patient to tolerate. This is an example of
excessive and severe reactions in a tissue that is unable to
absorb the changes and return to relative normality. In
other words, there are situations in chemotherapy when
Table 1: The types of reactions seen in the treatment of 
onchocerciasis with oral diethylcarbamazine, ivermectin* and 
others
EXPECTED ("ACCEPTABLE") REACTIONS
• "Classical Mazzotti reactions"
Pruritus
Papular dermal response
Dermal edema
Headache
Nausea
Lethargy
EXCESSIVE ("UNACCEPTABLE") REACTIONS
• Excessive forms of the normally expected Mazzotti reactions
Temporal association with treatment
Lethargy
Papular, pruritic, and edematous dermal responses
Severe headache
Bone ache
Inability to work
Prostration (e.g. Sowda patients)
• Major neurological changes
Coma
Epilepsy
• Specific (non-Mazzotti) dermal responses
Drug-related allergic responses (dermal plaques etc.)
• Other responses
Unsubstantiated reports (bleeding, etc.)
* Ivermectin produces reactions significantly less in severity and 
duration.
Table 2: The major components associated with microfilarial 
destruction.
NATURAL SITUATIONS
DERMAL RESPONSES
• Clinical
Pruritus
Self-destruction of the skin (mechanical)
Development of dermal microabscesses
• Histopathological
Vascular endothelial activation
Mast cell increase
Blood and tissue eosinophilia
Eosinophil adherence to the surface of the microfilariae
Macrophage accumulation
Fragmentation of microfilariae
Local tissue damage (destruction of collagen, etc.)
SYSTEMIC EFFECTS
• Antigen release
• Organ dysfunction
• Cytokine circulation
DRUG INDUCED SITUATIONS (additional activities):
GENERAL (in addition to those activities in Natural Situations)
• Clinical
Migration of microfilariae
Increased rate of Mf destruction,
More rapid and severe development of the events
Progressive movement of the papular response over different parts 
the body (with low dose DEC)
• Histopathological
Macrophage ingestion of excess eosinophil-derived material
Evidence of immunostimulationFilaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S5
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the body cannot easily handle the reactions that develop
associated with the degenerating microfilariae.
Inflammation associated with Mf destruction and
removal probably includes all of the basic inflammatory
phenomena, including cytokine release, immune com-
plex formation, autoimmune responses and various phys-
ical events, all often resulting in tissue damage. High
levels of immune responses are found in onchocerciasis
patients, reflecting the heavy antigenic burden and very
active antibody responses that are hallmarks of this infec-
tion; their pathological significance remains unclear. Nei-
ther peripheral lymphoid tissues, nor the liver or kidney
(or other organs that might process such complexes) are
notably compromised in these patients. Thus, there is no
definitive evidence for a central involvement of immune
complexes in the pathogenesis of ivermectin-associated
adverse reactions. That anti-inflammatory drugs (e.g. cor-
tisone, antihistamines) cannot completely suppress the
immunological events associated with Mf destruction
emphasizes the complex balance among the various path-
ways activated.
These microfilarial reactions have been investigated and
described in most detail with DEC treatment, but in all
likelihood similar phenomena occur with reactions to
other Mf such as Loa loa.
Clinical problems encountered in the 
chemotherapy of onchocerciasis patients
Non-Serious
Remarkably few serious reactions are reported with the
use of ivermectin in humans or in most animals. In
general, the signs and symptoms, which vary in duration
(usually no longer than four days), include nausea, head-
ache, minor fever and dermatological responses associ-
ated with the presence of dying MF in the skin; pruritic
injection of the conjunctiva has also been reported. These
Mazzotti-type reactions are similar in many respects to
those seen with other microfilariacidal agents, such as
DEC [15], although lesser in extent and intensity than
with the latter drug.
The unacceptability of these reactions with DEC, espe-
cially as associated with an adverse effect on ocular tissues
(inducing loss of vision), and the severity of these dermal
reactions in many people, drove the search for new and
safer agents. Ivermectin filled many of the requirements,
including a lack of pathology in the ocular tissues, high
microfilaricidal efficacy, long lasting Mf suppression and
much reduced severity of associated dermal reactions. It
was thus adopted as the drug of choice for the treatment
of onchocerciasis.
Serious
General
Most adverse reactions to treatment with antifilarial drugs
occur in the period shortly after the administration of the
drug, i.e. usually "discomforting" and are short lived.
Only when they persist, or are of severe intensity, do they
become matters of medical concern. There have been one
or two anecdotal reports of serious clinical responses that
are consistent with classic allergic reactions to the drug
itself. Given the number of doses (tens of millions) that
have been administered in the Control Programs as a
whole, true ivermectin drug hypersensitivity cases are
extremely rare. The serious drug reactions are summarized
in Table 1.
The situation in Cameroon: Associated with Loa loa co-infection?
An apparent exception to the ivermectin success story has
been the situation involving the exceptionally serious
CNS reactions observed in a small number of people, and
proposed to be related to the presence of concurrent high
burdens of Loa loa Mf. In 1996, cases of coma and death
began to appear in Cameroon [5–7,16,17]. To date, 46
cases of this syndrome have been recorded, with 22 fatal-
ities. The condition has probably been under-reported,
with possibly up to 80 fatalities out of ~300 cases of the
syndrome actually having occurred in Cameroon (Bouss-
inesq, personal communication). Limited medical infor-
mation is available on most of the cases due to the rural
location in which the cases occurred and the understand-
ably minimal local medical support system at hand. The
fatalities in Cameroon occurred with patients who had
high loads of circulating L. loa Mf, and this association has
raised great concern among local medical officials, pro-
gram directors and the scientific community alike. These
cases have been defined as "Loa loa-associated adverse
reactions" and have the characteristics of a gradually
developing encephalopathy (Table 3). It is important to
note that co-infection with O. volvulus and L. loa is found
in many other regions, and that these kinds of very severe
reaction have only been reported from Cameroon. The
apparent geographic restriction of the phenomenon must
be incorporated into any analysis of the pathology of this
condition.
Serious CNS pathology has been previously reported with
DEC treatment of patients with Loa loa infection; these
have some clinical similarities as the current Loa-associ-
ated cases treated with ivermectin. Ducorps and col-
leagues [18] reported significant adverse reactions in
patients with loiasis, particularly those with >30,000 mf/
ml in their circulation; these changes included fever, pru-
ritus, headache, arthralgia, disturbed consciousness
(obnubilation), as well as the more significant coma and
renal impairment. The symptoms in these cases occurred
a little earlier than those with ivermectin (i.e. within 24–Filaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S5
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36 hr of dosing) but did show progressing neurological
severity. Other reports such as that of Carme et al., [19],
which presents 5 cases showing fever and coma 9–18 days
after DEC treatment (with one at day 3) have distinct sim-
ilarities to the present cases. Downie [20] has also
reviewed cases of complications after DEC treatment in
loiasis patients. Thus there may be a similar etiologies in
the pathology induced by these two drugs, i.e. the effects
being primarily related to the death of microfilariae in
CNS tissue and ensuing inflammation.
Eye lesions have been reported after DEC treatment of loi-
asis patients, as is seen in the current ivermectin cases in
Cameroon. Toissant and Danis [21] found retinal hemor-
rhages and saccular microaneurysms associated with the
degeneration of the associated cells such as pericytes. Mf
were associated with at least 25% of these lesions. Like-
wise, hemorrhages have been seen in the conjunctiva and
the retinal fundus of the current ivermectin treated Loa
patients [22]. Importantly, these vascular lesions closely
resemble ocular findings in malaria where it is believed
that parasitic micro-emboli are an integral component of
their pathogenesis. These, therefore, may represent the
results of microemboli of Loa loa Mf. Interestingly, Man-
sonella perstans Mf were seen to be associated with the pres-
ence of the lesions [23] in the DEC cases, but this
observation requires substantiation.
Other records of CNS and ocular pathology exist in rela-
tionship to the presence and treatment of loiasis. Of spe-
cial interest is the report by Langois et al., [24], who
showed obstruction to the central retinal artery in loiasis.
Other reports describe various forms of neuropathology,
including encephalitis, cerebral destruction with clinical
hemiplegia, meningitis, and peripheral neuritis [25,26].
In the current cases reactions in the cranial cavity to drug-
damaged adult parasites should not be ruled out, as severe
and fatal outcomes occur in other CNS nematodiases,
such as infections with Angiostrongylus cantonensis. There
is, however, little evidence for a short-term adulticidal
activity for ivermectin.
The similarities between these DEC-induced microfilar-
iae-related pathologies and those that are appearing in the
patients with the present Loa-associated syndrome sup-
port the hypothesis that the SAE in the latter group
involve pathology associated with microfilarial death and
destruction.
Possible pathogenic bases for adverse reactions 
seen after chemotherapy
In general the possible causes of the adverse reactions
associated with antifilarial drugs can be considered in two
major groups: pathological events and mechanisms
involving a) the drug having a direct toxic effect on the
host, and those involving b) the parasite-drug interaction
effecting the host (Table 4).
Ivermectin and its structural analogs have been given to
tens of millions of people and hundreds of millions of
animals, with remarkably few severe reactions. Toxic con-
sequences of administration of standard doses of a drug
generally have two primary explanations:
1) The toxicity represents natural variation in sensitivity to
any chemical compound, and represents a linear scale
from trivial to serious [27].
2) Alternatively, toxicity is unrelated to more common
untoward effects, and reflects a unique pharmacological
action of the drug that could not be anticipated as simply
the outer fringe of the normal distribution of responses
(either therapeutic or toxic). In such a case, the toxic con-
sequence represents an idiosyncratic response.
Table 3: Major clinical characteristics of patients with loa-
associated adverse reaction syndrome – "loa encephalopathy" *
PRESENT:
• Comatose condition with 4 days of treatment with ivermectin
• Microfilariae blood levels > 8000 Mf/ml
• Resident in an onchocerciasis meso- or hyper-endemic area
• Early fever
• Developing neurological symptoms and signs
• Gradual worsening (to coma) (basal ganglia)
• Retinal or conjunctival hemorrhages +/-
• Renal damage +/-
• Drop in Mf load
• Movement of Mf into CSF and urine (extra vascular)
OUTCOMES
• Coma – encephalopathy
• Death
• Secondary infections (poor nursing)
• Hypoglycaemia
• Persistent fever, sepsis
• Dehydration
• Abdominal pain
• Urinary complications
OTHER SIGNIFICANT OBSERVATIONS:
• No dermal reactions
• No acute Mazzotti reactions
• No allergic phenomenon (obvious non-parasitic, lung wheezing 
etc.)
• No cardiac complications
• No hepatic involvement (?)
• No bleeding
• No cerebral edema
• No fundal edema
• No convulsions
* Adapted from Reference [17].Filaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S5
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The serious clinical events observed in this Cameroonian
group represent a tiny percentage of the total treated pop-
ulation. The most striking consequence is the onset of
coma. This response could not have been easily antici-
pated since adverse neurological effects have not been
described in treated populations. That is, we see no evi-
dence for an escalating incidence of side effects,
progressing from mild sleepiness or dizziness through
slurred speech and ataxia to frank coma, in any popula-
tion treated with ivermectin. Therefore occurrence of
coma in these patients likely reflects an idiosyncratic
response, one that could not be anticipated from the more
common side effects seen in other patients in this same
population or in populations treated for similar infections
(e.g., lymphatic filariasis).
Given that the mechanism of microfilaricidal activity of
ivermectin requires the intervention of immune effectors,
there are two possible explanations for an idiosyncratic
response to the drug in dually infected patients:
1) The response has nothing whatsoever to do with para-
sitism, and would be observed in these patients even if
they were free of filariae, or
2) The response reflects an atypical outcome of the
immune response to Mf in the presence of ivermectin.
These possibilities must be evaluated in light of clinical
experience obtained with ivermectin in veterinary and
human medicine.
The target for the antiparasitic effects of ivermectin is a
group of glutamate-gated Cl- channels unique to inverte-
brates [28], which this drug profoundly and persistently
opens. This action disrupts the regulation of transmem-
brane potential in invertebrate neuromuscular systems,
leading to paralysis of critical muscles and the consequent
demise of the organism. However, the drug also potently
opens structurally related Cl- channels that are gated by
GABA [29], which are broadly expressed in the mamma-
lian CNS. The remarkable therapeutic index of these com-
pounds in mammals is due only in part because
mammals completely lack glutamate-gated Cl- channels.
Instead, mammals are protected from ivermectin toxicity
not by the absence of the molecular target, but by the pres-
ence of an effective blood-brain barrier that prevents
access of the drug to a susceptible protein target in the
CNS [30–33].
Work done in knock-out mice revealed (inadvertently)
that exclusion of ivermectin from the CNS is due solely to
the function of a specific subtype of P-glycoprotein, a pro-
tein family that translocates hydrophobic compounds
across cell membranes (associated in the past with
resistance of tumor cells to anticancer drugs). Disruption
of the mdr1a locus in mice rendered them highly sensitive
to ivermectin toxicity when the drug was given to control
an outbreak of parasitism in the transgenic colony [34].
The primary toxicity was coma. That a small percentage of
certain breeds of dogs (some collies and shepherds) also
became comatose when dosed with ivermectin for heart-
worm prevention had also been long known [35].
Recently, it has been shown conclusively that susceptible
dogs have inactivating mutations in the mdr1a gene
[36,37]. The consequence of allowing ivermectin accumu-
lation in the brain is a prolonged and progressive CNS
intoxication in both dogs and mice, resulting in coma.
Could a similar phenomenon explain the apparent idio-
syncratic toxic reactions observed in Cameroon? It would
not be surprising to find that loss-of-function mdr1a
mutations exist in humans, as they do in dogs. There is no
evident phenotype for the mutation in dogs other than
acute sensitivity to ivermectin and a few other drugs. It
would also not be surprising to find that such a mutation
would be geographically restricted [40], found perhaps at
a detectable frequency in one or a few populations
exposed to ivermectin (a rare event in wealthy countries).
Indeed, one might almost predict the eventual appearance
of ivermectin toxicity in a human population from an
analysis of the situation observed in canines.
It would be relatively simple to rule out the possibility
that loss-of-function mutations in the human mdr1a gene
underlie ivermectin toxicity. The sequence of this gene is
known and it could be cloned from peripheral lym-
Table 4: The parasite and host mechanisms possibly involved in 
loa-associated encephalopathy
PARASITE RELATED MECHANISMS
• Massive movement and death of parasite clumps in vessels → 
embolic blockage → local vascular inflammation and subsequent 
tissue damage in sensitive tissues (similarities to  malaria)
• Reactions against dying adult worms or wandering larvae?
• Due to two or more parasite species being present
PATIENT RELATED MECHANISMS
PATHOLOGICAL
• Effects of alcohol (co-administration and/or chronic changes)
• Effects of food (co-administration)
• Gut disease (increasing uptake)
• Altered processing (liver damage)
• Other co-existent infections or disease processes
• CNS Toxicity (overdose)
• Allergic drug sensitivity (rare)
GENETIC
• Blood Brain Barrier Alterations
Mdr1 mutation – homozygous
Human equivalent to dogs, mice, knockout mice and cattle
• Polymorphism to inflammation
Pro- versus anti-inflammatory cytokine expression
• Genetic predisposition to microfilariaemiaFilaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S5
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phocytes obtained from survivors of ivermectin-induced
coma or relatives of victims (the phenotype is probably
recessive, so heterozygotes may be unaffected and would
be more common in the local population). Analysis of
this locus will reveal whether lessons learned from dogs
can be usefully applied to humans. Given the background
and overall resemblance of the syndrome in dogs and
affected humans, the conservative approach is to first
determine whether a common molecular basis exists.
If this hypothesis proved to be correct, treatment pro-
grams could be continued without regard to coincident
infections with L. loa. There is no simple and cheap diag-
nostic test that could pre-screen local populations that
had not yet been dosed with ivermectin for evidence of
mdr1a mutations. However, the phenotype is, on the evi-
dence, exceedingly rare, and treatment could resume as
long as the incidence of CNS sequelae following treat-
ment was closely monitored. It is conceivable that a cost-
effective PCR-based diagnostic test could be implemented
to identify individuals in villages where serious adverse
reactions were observed who should be excluded from
treatment.
The possibility of the adverse reactions being directly
related to microfilarial events, such as their death and
destruction, has been proposed. In all likelihood antimi-
crofilarial agents such as DEC and ivermectin function
either in conjunction with, or at least enhanced by, host
immunological or inflammatory components. It is impor-
tant to note that neither DEC nor ivermectin have
detectable effects on microfilarial motility or viability in
culture at pharmacologically relevant concentrations.
Understanding how these drugs work to stimulate
immune-dependent killing of Mf is an important step in
clearly understanding the clinical reactions associated
with them. Conversely we should also understand how
these relatively large parasites manage to survive in large
numbers without attracting attention from the host
immune system. The mechanisms by which these para-
sites suppress recognition and destruction by the host
must be the targets for DEC and ivermectin. Unfortu-
nately these questions are difficult to address.
The clinical presentation of these patients and a consider-
ation of the literature points clearly to the involvement of
an inflammatory process, this probably leading to the
coma and possibly hepatic dysfunction. One line of inves-
tigation would be to determine if the individuals suffering
from the adverse effects have a perturbed cytokine
response that predisposes them to an excessive inflamma-
tion. These individuals could be typed for cytokine pro-
files; this could be done retrospectively on survivors of
adverse incidents. If predisposition was found to be the
case then it might be possible to screen high Loa loa micro-
filariae carriers to determine those at greatest risk; how-
ever, this may not be practical in the field situation. The
possibility exists that gene-controlled variation in specific
immune response lies at the base of these idiosyncratic
reactions to ivermectin [38]. There are many factors that
contribute to an individual's response at a particular point
in time: including the parasite load, the state of immune
system (its immunosuppressive or stimulatory state), as
well as the ability or inability to efficiently clear killed par-
asite material. However, a major factor that may be at play
in these cases is the individual's own genetic predisposi-
tion towards either TH1 or TH2 responses [39] when chal-
lenged by stimuli, i.e. an individual responds with a
predictable profile influenced or guided by their genetics.
It could be important to determine which of the polymor-
phic alleles of several cytokine genes governs this phe-
nomenon. Individual genetic variation could therefore be
important to understanding this clinical phenomenon. It
may be that the affected individuals in these cases have a
predisposition to drive inflammatory responses to dying
Mf to clinically unacceptable levels in such sensitive target
organs such as the CNS. The fact that not all of the indi-
viduals with high microfilarial loads are affected by the
encephalopathy is interesting in this light.
Approaches to the Problem
There is a medical and moral need to move quickly to the
next step of proposing actions regarding these SAEs. These
actions include managerial and political activities, but
there are also scientific questions that must be answered
to provide a more rational approach to this problem. To
put this problem in perspective it should be noted that in
the drug industry, this level of adverse reactions (1 case in
12,000,000 administrations) would be regarded as being
comparatively low. Nevertheless, it is important consider
the ramifications of the toxicity from the perspective of
the state or community in which they occurred, and their
immediate implications for onchocerciasis control pro-
grams there and elsewhere. There is an urgent need to pro-
ceed to a policy based on practical action to moves us
ahead. What this action should be is open for discussion,
but there a number of options and possibilities. The
authors believe they must include research to better
understand the scientific basis of the phenomenon, as
well as steps that lead to responding to the field situation
with appropriate levels of assessment and monitoring.
It is important to discriminate among the possible expla-
nations for the pathogenesis of the L. loa associated syn-
drome, whether or not further fatalities unfortunately
occur. It would be straightforward to examine the possi-
bility of genetic polymorphisms in mdr1a genes or inflam-
matory responses in a population sample obtained from
the geographic locale of the main cluster of cases. Careful
prospective monitoring of the geographic distribution ofFilaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S5
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the occurrence of CNS reactions after ivermectin treat-
ment in loiasis patients across the endemic areas will con-
firm or disprove the geographic restriction of the SAEs,
pointing to human genetic variation as a key explanation
of the syndrome. Further work to characterize the possi-
bility of a micro-embolic pathology similar to that seen in
malaria is also important. Direct examination of CNS tis-
sues will reveal crucial data; core sampling of brain tissues
after death, which requires minimal invasion of the body,
is arguably the best approach. CSF fluid should be moni-
tored for cellular content, glucose content and proteins
such C-reactive proteins. Other potentially useful labora-
tory parameters include ivermectin concentration in CSF,
eosinophil products and indicators of fibrin deposition,
fibrin degradation products (FDPs), endothelial and
platelet activation and hemorrhage.
What is the most likely pathogenesis?
Two major explanations for the fatal SAEs associated with
L. loa infections in Cameroon currently seem the most fea-
sible. Firstly, that the condition is directly related to Loa
microfilariae and the development of a CNS centered
micro-embolic vascular pathology with associated inflam-
matory reactions due to the parasite death and the intra-
vascular clumping (supported by the clinical evidence of
retinal and conjunctival hemorrhages); this has parallels
with the micro-embolic events seen in malaria. Such
events may be more severe in patients with a predisposi-
tion to excessive inflammatory responses occurring with
microfilarial death. There may be predisposition for L. loa
Mf to be trapped specifically in the CNS vasculature,
promoting problems in this organ when chemotherapy
begins to destroy the parasites. Increased migration of Mf
appears also to be an important event after therapy and
this may enhance the formation of embolic inflammatory
foci of the dying parasites. The timing of clinical manifes-
tations of the ensuing inflammatory and anoxic pathol-
ogy after the 3rd and 4th days of treatment supports this
theory.
Secondly, there may be a genetic susceptibility in the
affected patients that allows ivermectin to accumulate in
the CNS, causing a toxicity similar to that seen in dogs and
mice. The apparent geographic clustering supports this
hypothesis of a genetic predisposition and one cannot
help but wonder if the human equivalent of the mdr-1
abnormality described in animals has now been found in
humans. A genetically influenced inability to handle and
absorb parasite induced-inflammation might also be in
play.
Other mechanisms could very well be at play, but much
more detailed clinical and pathological analyses is needed
before definitive statements can be made about the cause
of these fatal SAEs. Confounding circumstances appear
unlikely. No association with locally common infections
(such as malaria) has been seen. The only parasitic infec-
tion so far correlated with the occurrence of the serious
reactions is loiasis; nonetheless, it would be wise to keep
open the possibility of other co-infections. It has been
suggested that alcohol intake may play a role in predispos-
ing individuals to develop severe reactions to ivermectin
by changing its pharmacokinetic behavior. However, this
does not appear to be the case, as locally produced alco-
holic beverages do not increase blood levels of ivermectin
(Homeida et al., unpublished).
Any research-oriented approaches to addressing this prob-
lem should be matched with actions at the community
level. These should include the establishment of clear
medical guidelines for the responding medical and sup-
port staff, improving procedures to screen for high Mf
load carriers, and developing better messages for the peo-
ple living in the endemic areas where these fatalities occur.
It is essential to address the medical, public and political
challenges that the ivermectin-associated serious adverse
reactions present, and to thus ensure the continuation of
a medically sound chemotherapy program.
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